Amino Acid, Peptide, or Protein

Ultragenyx and Mereo BioPharma Stocks Crash After Late-Stage Setrusumab Trials Fail in Osteogenesis Imperfecta

5 hours ago talkbio0Tagged Bone Density, Clinical trial failure, Mereo BioPharma, Osteogenesis Imperfecta, setrusumab, Stock Crash, Ultragenyx

Ultragenyx; Mereo BioPharma; setrusumab; osteogenesis imperfecta; clinical trial failure; stock crash; bone mineral density

Lunit SCOPE AI Achieves High Concordance in HER2 Assessment for Biliary Tract Cancer

14 hours ago talkbio0Tagged Agreement, Biliary Tract Cancer, erbB-2 Receptor, Lunit SCOPE, Medical pathologist, Pathology

Lunit SCOPE; HER2; biliary tract cancer; AI pathology; concordance; pathologists

Patient Dies from Thrombotic Stroke in Pfizer’s Hympavzi Hemophilia Trial After Minor Surgery

1 week ago talkbio0Tagged Clinical Trials, Hemophilia A, HYMPAVZI, marstacimab, Patient Death, Pfizer, Thrombotic Stroke

Pfizer; Hympavzi; marstacimab; hemophilia; thrombotic stroke; patient death; clinical trial

Neurocrine’s VMAT2 Inhibitor Valbenazine Fails in Phase 3 Trial for Dyskinetic Cerebral Palsy

1 week ago talkbio0Tagged Athetoid cerebral palsy, Chorea, KINECT-DCP, Neurocrine, Phase 3 trial, valbenazine, VMAT2 Inhibitor

Neurocrine; valbenazine; VMAT2 inhibitor; dyskinetic cerebral palsy; KINECT-DCP; Phase 3 trial; chorea

Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment

1 week ago talkbio0Tagged Approved, Glucagon-Like Peptide 1, Novo Nordisk, Obesity, oral semaglutide, United States Food and Drug Administration, Wegovy pill

Novo Nordisk; Wegovy pill; FDA approval; oral semaglutide; obesity treatment; GLP-1

White House unveils nine new “most-favored-nation” drug pricing deals

2 weeks ago talkbio0Tagged drug price, eli lilly, Health Policy, MFN, Most-Favored-Nation, Nordisk, Ozempic, pharmaceutical manufacturers, prescription drug costs, Trump administration, U.S., Wegovy, White House

most-favored-nation pricing; MFN; drug pricing; White House; Trump administration; pharmaceutical manufacturers; Ozempic; Wegovy; Eli Lilly; Novo Nordisk; prescription drug costs; US healthcare policy

GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics

2 weeks ago talkbio0Tagged Antisense Oligonucleotides, Antistreptolysin O, CAMP4, Collaboration, gene upregulation, Kidney Diseases, LRPAP1 gene, milestone payments, Neurodegenerative Disorders, Platform, regulatory RNA, RNA therapeutics, royalties, SmithKline Beecham

GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

2 weeks ago talkbio0Tagged Approved, Clinical Trials, Eli, Glucagon-Like Peptide 1, injectable incretins, national priority review voucher, Obesity, Oral cavity, orforglipron, Phase 3 trial, United States Food and Drug Administration, Wegovy, weight maintenance, Zepbound

Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial

Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

2 weeks ago talkbio0Tagged compounding pharmacy, East Windsor facility, Empower Pharmacy, Facility (object), Glucagon-Like Peptide 1, Inspection (procedure), layoffs, manufacturing shutdown, New Jersey operations, Outsourcing, Qualitative form, United States Food and Drug Administration, Workforce reduction

Empower Pharmacy; compounding pharmacy; layoffs; job cuts; New Jersey operations; East Windsor facility; manufacturing shutdown; outsourcing facility; FDA inspection; Form 483; compounded GLP-1 drugs; workforce reduction

Padcev-Keytruda Combination Succeeds Again in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

2 weeks ago talkbio0Tagged EV-304, Event-Free Survival, KEYNOTE-B15, Keytruda, Malignant neoplasm of urinary bladder, Padcev

Padcev; Keytruda; bladder cancer; KEYNOTE-B15; EV-304; event-free survival